Page 100 - 南京医科大学学报自然科学版
P. 100

南京医科大学学报(自然科学版)                                  第42卷第8期
               ·1142 ·                    Journal of Nanjing Medical University(Natural Sciences)   2022年8月


             ·临床研究·

              TIPS联合PTVE治疗自身免疫性肝硬化曲张静脉出血疗效分析



              吴军政,刘 圣,施海彬,杨 魏,田 伟,周海峰,周卫忠                       *
              南京医科大学第一附属医院介入放射科,江苏 南京                   210029




             [摘    要] 目的:探讨经颈静脉肝内门体分流术(transjugular intrahepatic portosystemic stent shunt,TIPS)联合曲张静脉栓塞
             (percutaneous transhepatic variceal embolization,PTVE)治疗自身免疫性肝病(autoimmune liver diseases,AILD)后肝硬化患者食
              管胃底曲张静脉破裂出血的安全性和有效性。方法:回顾性分析2015年8月—2021年9月南京医科大学第一附属医院收治的
              23例AILD后肝硬化合并食管胃底曲张静脉破裂出血患者(男2例,女21例)的临床资料。所有患者在保守治疗和/或内镜治疗
              失败后均接受了TIPS联合PTVE治疗。评估患者的即刻出血控制率、再出血率、无再出血生存期、总生存期和并发症。结果:
              患者即刻出血控制率为100%。1年、2年和3年的累计再出血率分别为9.6%、17.1%和17.1%。无出血生存时间70~1 308 d,中
              位时间455 d。1年、2年、3年的累计生存率分别为100.0%、91.7%和91.7%。生存时间85~1 308 d,中位时间611 d。严重的短
              期并发症包括急性心功能不全1例,腹腔出血1例。长期并发症包括4例脑性脑病,1例为West Haven Ⅲ级,另3例为West Ha⁃
              ven Ⅱ级。结论:TIPS联合PTVE治疗AILD后肝硬化患者的食管胃底曲张静脉破裂出血可能安全有效。
             [关键词] 经颈静脉肝内门体分流术;自身免疫性肝病;食管胃底静脉曲张出血
             [中图分类号] R3815                     [文献标志码] A                      [文章编号] 1007⁃4368(2022)08⁃1142⁃05
              doi:10.7655/NYDXBNS20220814


              Transjugular intrahepatic portosystemic stent shunt combined with percutaneous
              transhepatic variceal embolization for variceal bleeding in liver cirrhosis caused by

              autoimmune liver diseases

              WU Junzheng,LIU Sheng,SHI Haibin,YANG Wei,Tian Wei,ZHOU Haifeng,ZHOU Weizhong   *
              Department of Interventional Radiology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,
              China


             [Abstract] Objective:This study aims to investigate the safety and efficacy of transjugular intrahepatic portosystemic stent shunt
             (TIPS)combined with percutaneous transhepatic variceal embolization(PTVE)in the treatment of esophagogastric variceal bleeding in
              liver cirrhosis caused by autoimmune liver diseases(AILD).Methods:From August 2015 to September 2021,the clinical data of 23
              patients(2 males and 21 females)with esophagogastric variceal bleeding in liver cirrhosis caused by AILD were retrospectively
              analyzed. All patients received TIPS and PTVE treatment after conservative and/or endoscopic treatment failed to control bleeding. The
              immediate bleeding control rate,rebleeding rate,rebleeding⁃free survival,overall survival and complications were evaluated. Results:
              Patients showed a high immediate bleeding control rate(100%). The 1⁃,2⁃,and 3⁃year rebleeding rate were 9.6%,17.1%,and 17.1%,
              respectively. The median rebleeding⁃free survival time was 455 days(range:70⁃1 308 days). The 1⁃,2⁃,3⁃year survival rate was 100%,
              91.7% ,and 91.7% ,respectively. The median overall survival time was 611 days(range:85 ⁃ 1 308 days). The severe short ⁃ term
              complications included acute cardiac insufficiency(1 case)and intra⁃abdominal hemorrhage(1 case). Long⁃term complications were
              hepatic encephalopathy(4 cases),with West Haven grade Ⅲ in 1 case and West Haven Grade Ⅱ in other 3 cases. Conclusion:TIPS
              combined with PTVE may be safe and effective in the management of esophagogastric variceal bleedingin liver cirrhosis caused by
              AILD.
             [Key words] transjugular intrahepatic portosystemic stent shunt;autoimmune liver diseases;esophagogastric variceal bleeding
                                                                           [J Nanjing Med Univ,2022,42(08):1142⁃1146]

             [基金项目] 国家自然科学基金项目(81701802)
              ∗
              通信作者(Corresponding author),E⁃mail:xmjbq007@163.com
   95   96   97   98   99   100   101   102   103   104   105